Unknown PHASE3 INTERVENTIONAL 2-arm NCT00261326

Simvastatin Treatment of Patients With Acute Optic Neuritis

Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial

Sponsor: Alpharma ApS

Conditions Multiple Sclerosis Optic Neuritis

Interventions placebo simvastatin

Updated 6 times since 2017 Last updated: Jan 7, 2011 Started: Sep 30, 2006 Primary completion: Jan 31, 2010 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00261326, this PHASE3 trial focuses on Multiple Sclerosis and Optic Neuritis and remains ongoing. Sponsored by Alpharma ApS, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alpharma ApS
Glostrup University Hospital, Copenhagen

Data source: Glostrup University Hospital, Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glostrup Municipality, Denmark